"The neuroClues device is a portable, connected headset that captures up to 800 infrared images per eye per second as a patient visually tracks a moving target on screen. Its AI models then extract oculomotor biomarkers within minutes, providing neurologists with objective, quantifiable measurements that can indicate the presence of neurological disorders including Parkinson's disease, Alzheimer's disease, and multiple sclerosis."
"The company was founded in 2020 as P3Lab by Antoine Pouppez, Pierre Daye, and Pierre Pouget, the latter two being neuroscience researchers with more than 35 combined years studying oculomotor function. The research basis for using eye movements to detect neurological conditions has a long history: Pouppez has noted that the first scientific paper linking eye tracking to neurological diagnosis dates to 1905."
neuroClues, a French-Belgian medtech company, has developed an AI-powered eye-tracking device that captures up to 800 infrared images per eye per second. This device extracts oculomotor biomarkers to indicate neurological disorders like Parkinson's, Alzheimer's, and multiple sclerosis years before symptoms manifest. The company secured €10 million in Series A funding following CE certification for its Class IIa medical device in January 2025. Founded in 2020, neuroClues aims for FDA clearance in 2026, enhancing early diagnosis in clinical settings without requiring calibration.
Read at TNW | Startups-Technology
Unable to calculate read time
Collection
[
|
...
]